anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, edoxaban
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2014 Mar 15;383(9921):955-62 Meta-Analysis
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, edoxaban
As Treatment, Chronic
Is better Than
anticoagulants, antivitamine K, warfarin
To reduce reduced stroke or embolic events (RR 0.81), mainly driven by a reduction in haemorrhagic stroke (RR 0.49). New oral anticoagulants also reduced all-cause mortality (RR 0.90) but increased gastrointestinal bleeding (RR 1.25)
Circulation. 2015 Jul 21;132(3):194-204 Systematic Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, thromboembolic disease, old patients The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, edoxaban
As Treatment, Chronic
Is equal Than
anticoagulants, antivitamine K, warfarin
To reduce thrombo-embolic events, but with different bleeding patterns: dabigatran was associated with a higher risk of gastrointestinal bleeding, risk of intracranial bleeding was lower, apixaban and edoxaban associated lower risk of major bleedings